BMRN's Quality Score rose 2 points on Tue, Nov 10, to -1. Trading was quieter than usual (2 chart checks started).
Follow BMRN's trial news. Pro members can get an alert when BioMarin Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 32% over three years while the S&P 500 rose 80%.
| Since its 2023 high | Down 51% |
| Latest filing | 10-Q, Nov 3 |
Wed Nov 11: Stifel Healthcare Conference 2026Investor conference · date confirmed.
3 more dates ahead: conferences, for Pro members.
After its last 4 reports it closed -0.9% on average, higher 1 of 4 times.
No shelf registration or at-the-market program on file in the last three years.
EVP, Chief Legal Officer George Eric Davis sold 17,557 shares on Sep 2. 4 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Poorfor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means
BMRN is #161 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 161 |
Free cash flow over four quarters: BMRN $558M, BBIO -$370M, MIRM -$274M.
Expected to report Mon Feb 22, after the close (in 104 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $1.0B, 32% more than a year ago; a loss of $0.63 a share, from $0.16.
“Total Revenues for the third quarter of 2026 were $1,025 million, an increase of 32% compared to the same period in 2025, primarily driven by revenues from GALAFOLD and POMBILITI + OPFOLDA, which were acquired on April 27, 2026, as well as 18% revenue growth in VIMIZIM due to timing of large international orders.”
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Product | $1B | $984M | $761M |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 3)
No outlook figures read from this release.
Sales grew 12% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 0.6% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 2, 2026 | -7.6% | -3.1% | -0.5% |
| Aug 6, 2026 | +5.5% | +3.8% | +11.5% |
| May 4, 2026 | +0.2% | -4.0% | -5.2% |
Sales grew in six of the last seven years, to $3.2B in 2025. It made a profit in five of the eight years.
RSI 49.8, MACD above signal, below both averages. Not scored.
One insider sold $1.2M across 1 filing in the last 6 months. No open-market buys on record. The newest:
One trade disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: BMRN is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
“The biopharmaceutical industry is rapidly evolving and highly competitive.”
BMRN scores -1 today, which Breakaway calls Poor. It is #161 of 281 in Biotech by Quality Score, with 4 of 14 chart checks firing. Down 32% over three years while the S&P 500 rose 80%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
BMRN scores -1 today, which Breakaway calls Poor (below zero). That is #161 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind BMRN's -1.
One insider sold $1.2M across 1 filing in the last 6 months. No open-market buys on record. The newest is George Eric Davis, EVP, Chief Legal Officer, who sold $1.2M on Sep 2.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.